In conclusion, our results suggest that, for postmenopausal patients with BC and those with luminal B/Her2-negative subtype tumors, pretreatment NLR may provide additional information regarding the likelihood of achieving a pathologic complete response to neoadjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.